SATISFY‐JP, a phase II multicenter open‐label study on Satralizumab, an anti‐IL‐6 receptor antibody, use for the treatment of pulmonary arterial hypertension in patients with an immune‐responsive‐phenotype: Study protocol
2023 · Pulmonary Circulation · 9 citations
https://doi.org/10.1002/pul2.12251